Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | CEL | P19835 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949704 | 0.91 | DAO (0.41) | SIGMAR1CELOPRM1OPRD1OPRK1 | |
| SCHEMBL9950489 | 0.81 | MAOA (0.41) | OPRM1OPRD1OPRK1MAOAMAOB | |
| SCHEMBL9949988 | 0.81 | CEL (0.43) | SIGMAR1SLC18A3CELCCR5GPR84 | |
| SCHEMBL24512658 | 0.78 | MAOA (0.42) | OPRM1OPRD1OPRK1MAOAMAOB | |
| SCHEMBL22125238 | 0.78 | MAOA (0.37) | OPRK1MAOAMAOB | |
| SCHEMBL18976829 | 0.77 | NPC1 (0.51) | SIGMAR1SLC18A3BCHE | |
| SCHEMBL6897427 | 0.77 | SLC6A3 (0.53) | MAOAMAOB | |
| SCHEMBL2197339 | 0.77 | SLC18A3 (0.46) | SIGMAR1SLC18A3OPRM1OPRD1OPRK1 | |
| SCHEMBL9949875 | 0.77 | DRD2 (0.38) | BCHEMAOAMAOB | |
| SCHEMBL9949517 | 0.77 | DRD2 (0.40) | BCHEMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | SIGMAR1 1928/4885SLC18A3 1087/4885CEL 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.